ILUMYA
PeakmAbtildrakizumab-asmn
BLAINJECTIONINJECTABLE
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ILUMYA (tildrakizumab-asmn) is interleukin-23 antagonists [moa]. First approved in 2018.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILUMYA (tildrakizumab-asmn) is a monoclonal antibody that selectively antagonizes interleukin-23 (IL-23), a key cytokine driver of inflammatory skin diseases. It is administered via subcutaneous injection and is indicated for patients with moderate-to-severe plaque psoriasis. The drug works by blocking IL-23 signaling, reducing the inflammatory cascade responsible for psoriatic plaques.
$32MPart D
PeakProduct is at peak lifecycle with modest Medicare utilization (1,822 claims in 2023), suggesting a stable but non-dominant market position within the IL-23 antagonist class.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ILUMYA is a mature, peak-stage biologic with modest but stable market penetration in psoriasis. Careers on this product focus on defending market share against competitive IL-23 antagonists and managing payer relationships in a competitive landscape. Strategic emphasis is on differentiation, patient persistence, and preparing for eventual biosimilar competition.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.